top of page
Recent Posts

New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damage

Cooper is leading a new nationwide clinical trial, conducted within the Children's Oncology Group (COG), for children and adolescents with relapsed acute myelogenous leukemia (AML) to test a drug, CPX-351, which has been designed to kill leukemia cells while minimizing damage to the heart.

Read more:

Search By Tags
bottom of page